The two human tankyrase isoforms, TNKS1 and TNKS2, are
members of the PARP family of proteins, which has received considerable
attention as a pool of potential anticancer targets. In a recent paper in J. Med. Chem., a team of researchers from
Sweden and Singapore use fragment-based methods to discover potent, selective
inhibitors of the tankyrases. This is a nice example of FBLD from academia.
The researchers used differential scanning fluorimetry (DSF)
to screen 500 fragments at 1 mM concentration each against TNKS2. In this
assay, the protein is mixed with a fragment and a fluorescent dye that binds to
the denatured form of the protein. When the mixture is heated, fragments that
bind the protein should stabilize it against thermal denaturation. Thus, fragment
binding can be detected by an increase in melting temperature (which is itself
inferred by an increase in fluorescence). As noted previously, people have very
different opinions of DSF; some folks swear by it, while others find that it
produces too many false positives and negatives.
The present paper is an excellent resource for those wanting
to try DSF for themselves; it provides clear experimental details and discussion
of some of the things that can go wrong. One recommendation is to validate hits
from the initial single-point assay by running dose-response curves over a wide
concentration, such as 5-4000 micromolar. Another interesting tip is to add the
protease chymotrypsin to the mix; doing so gave cleaner data, presumably by
chewing up mis-folded contaminants.
The 500-fragment DSF screen identified two fragments against
TNKS1, both of which were characterized crystallographically. The researchers
chose to pursue fragment 2 since the structure suggested that this had good
vectors for growing. Interestingly, removing the methyl group caused a complete
loss in activity – another example of the power of methyl groups, and a
sobering reminder of how subtle changes could make the difference between
finding a fragment or not.
Fragment 2 was already quite potent, and adding an aryl
substituent as in compound 11 further increased activity. Replacing the
fluorine with a chlorine was even better, but at the cost of solubility, so the
researchers added solubilizing groups and obtained potent, soluble molecules such
as compound 17. Compounds 11 and 17 were also soaked into crystals of TNSK2,
and the resulting structures overlay nicely with each-other as well as with the
structure of the initial fragment.
Dissociation constants and kinetic parameters of the more
potent molecules were determined by SPR, and although in general improvements
in affinity were driven by decreases in koff rates, kon
rates started to play a role with the more potent compounds. In another nice
vindication for DSF, the thermal shift correlated nicely with both the IC50
and Kd values.
Compounds 11 and 17 bind differently than other PARP
inhibitors, so the researchers tested compound 11 against six other PARPs and
found it to be quite selective. In fact, it is even 16-fold selective for TNSK2
over TNSK1. While that property may ultimately not be desirable in a
therapeutic, it should be useful for exploring the
biology.
Overall this is a lovely piece of work, and it does make a
good case for the utility of DSF. The fragments identified are quite potent; perhaps the technique really shines at finding these exceptional fragments.
I am very interested in the chymotrypsin angle. In my experience screening fragments against a panel of proteases, Chymo was a sponge. It was more promiscuous against fragments than just about any other protein bu BSA/HSA.
ReplyDelete